ImmunityBio responds to FDA concerns over promotional content

Stipple Bio raises $100M Series A to advance next-gen cancer therapies

The new capital is expected to fund the company through 2029

Lupin wins USFDA nod for generic Dapagliflozin tablets

Approval for 5 mg and 10 mg strengths, bioequivalent to Farxiga®, strengthens Lupin’s anti-diabetic portfolio in US market

Allergan Aesthetics opens cutting-edge AMI training center in Austin

The center combines rigorous scientific instruction with practical, hands-on training, equipping providers with the clinical, consultative, and business skills needed to deliver safe, effective, and patient-centered care

Aurobindo gets USFDA approval for Dapagliflozin with 180-day exclusivity

Immediate U.S. launch planned for Farxiga®-equivalent diabetes drug; opportunity pegged at $10.2 billion in annual market size

Aurobindo Pharma wins USFDA approval for generic Xigduo XR

Immediate U.S. launch planned for dapagliflozin-metformin ER tablets; addressable market estimated at $514 millionannually

Merck moves to seal $53-a-share takeover of Terns Pharmaceuticals

The acquisition aims to bolster Merck’s hematology portfolio with Terns’ lead oncology candidate, TERN-701

Thailand and GHIT Fund join forces to tackle infectious diseases

The collaboration promises expanded funding for Thai universities, research institutes, companies, and global research partners working in Thailand

Zydus gets USFDA final approval for generic Dapagliflozin with 180-day shared exclusivity

Immediate opportunity in the $10.2 billion U.S. market as the diabetes therapy will be manufactured at Zydus’ SEZ Ahmedabad facility

World Health Day: Late diagnosis, rising lifestyle diseases put young India at risk

Sharp increase in diabetes, hypertension and fatty liver in 30–50 age group